FDA approves first generic under-the-tongue suboxone

FDA approves first generic under-the-tongue suboxone

(HealthDay)—The first generic version of an under-the-tongue film to treat opioid addiction has been approved by the U.S. Food and Drug Administration.

The of Suboxone (buprenorphine and naloxone) film from Mylan Technologies Inc. and Dr. Reddy's Laboratories SA will be available in different strengths.

The brand name and generic films should be used as part of an overall treatment plan that includes counseling and psychosocial support, and may only be prescribed by Drug Addiction Treatment Act-certified prescribers, the FDA said.

Common side effects of these films include numbness, burning and inflammation in the mouth, headache, nausea, vomiting, , constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.

More information: More Information

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA approves first generic under-the-tongue suboxone (2018, June 18) retrieved 6 December 2023 from https://medicalxpress.com/news/2018-06-fda-under-the-tongue-suboxone.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

FDA approves once-monthly injection for opioid addiction


Feedback to editors